Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.59 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.59 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5202651 | 0.99 | CYP3A4 (0.58) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Hydrochloric Acid SCHEMBL7429773 | 0.91 | HTR6 (0.51) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL7432465 | 0.87 | CYP3A4 (0.47) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL19679596 | 0.85 | KCNH2 (0.63) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL3994326 | 0.84 | KCNH2 (0.61) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Hydrochloric Acid SCHEMBL7410840 | 0.84 | CYP3A4 (0.43) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL5234561 | 0.83 | KCNH2 (0.53) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Hydrochloric Acid SCHEMBL10662186 | 0.83 | CYP3A4 (0.43) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL10665376 | 0.83 | CYP3A4 (0.43) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL10663734 | 0.83 | CYP3A4 (0.43) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499623-B1 | PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-¬(2-METHYL-1H-IMIDAZOL-1-YL)METHYL|-4H-CARBAZOL-4-ONE | TEVA GYOGYSZERGYAR ZARTKOERUEE (HU) | 2007-06-13 | — | — | EP | claimed |
| US-7098345-B2 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság (HU) | 2006-08-29 | — | — | US | claimed |
| US-20050020655-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2005-01-27 | — | — | US | claimed |
| US-10239866-B2 | Selective methods for the separation of ondansetron and related impurities | WATERS TECHNOLOGIES CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170197942-A1 | SELECTIVE METHODS FOR THE SEPARATION OF ONDANSETRON AND RELATED IMPURITIES | WATERS TECHNOLOGIES CORPORATION | 2017-07-13 | — | — | US | disclosed |
| US-20170197942-A1 | SELECTIVE METHODS FOR THE SEPARATION OF ONDANSETRON AND RELATED IMPURITIES | WATERS TECHNOLOGIES CORPORATION | 2017-07-13 | — | — | US | disclosed |
| US-7547791-B2 | One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O | IPCA LABORATORIES LTD. (IN) | 2009-06-16 | — | — | US | disclosed |
| US-7547791-B2 | One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O | IPCA LABORATORIES LTD. (IN) | 2009-06-16 | — | — | US | disclosed |
| US-7547791-B2 | One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O | IPCA LABORATORIES LTD. (IN) | 2009-06-16 | — | — | US | disclosed |
| US-20080009635-A1 | One-Pot Process for the Preparation of Antiemetic Agent, 1,2,3,9-Tetrahydro-9-Methyl-3[(2-Methyl)-1H-Imidazole-1-Yl)Methyl]-4H-Carbazol-4-O | IPCA LABORATORIES LIMITED (IN) | 2008-01-10 | — | — | US | disclosed |
| US-20080009635-A1 | One-Pot Process for the Preparation of Antiemetic Agent, 1,2,3,9-Tetrahydro-9-Methyl-3[(2-Methyl)-1H-Imidazole-1-Yl)Methyl]-4H-Carbazol-4-O | IPCA LABORATORIES LIMITED (IN) | 2008-01-10 | — | — | US | disclosed |
| WO-2004063189-A1 | ONDANSETRON FORMS AND PROCESSES OF MAKING THE SAME | SYNTHON B.V. (NL) | 2004-07-29 | — | — | WO | disclosed |
| US-20040019093-A1 | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2004-01-29 | — | — | US | disclosed |
| WO-2003093281-A1 | PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-[(2-METHYL-1H-IMIDAZOL-1-YL)METHYL]-4H-CARBAZOL-4-ONE | BIOGAL GYOGYSZERGYAR RT. (HU) | 2003-11-13 | — | — | WO | disclosed |
| EP-0595111-B2 | Carbazolone derivatives and process for preparing the same | RICHTER GEDEON VEGYESZET (HU) | 2001-08-16 | — | — | EP | disclosed |
| EP-0595111-B1 | Carbazolone derivatives and process for preparing the same | RICHTER GEDEON VEGYESZET (HU) | 1997-09-10 | — | — | EP | disclosed |
| US-5478949-A | Reacting the starting carbazolone with dialkyl oxalate, then formaldehyde and 2-methylimidazole | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1995-12-26 | — | — | US | disclosed |
| US-5416221-A | ONDANSETRON INTERMEDIATES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1995-05-16 | — | — | US | disclosed |
| EP-0595111-A1 | Carbazolone derivatives and process for preparing the same | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1994-05-04 | — | — | EP | disclosed |
| US-4695578-A | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances | GLAXO GROUP LIMITED (GB) | 1987-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020655-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | CYP3A4, HTR4, TPH1 | CYP3A4 1/4885KCNH2 948/4885CYP1A2 54/4885 |
| US-20040019093-A1 | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them | CYP3A43, CYP3A4, HTR3A | CYP3A4 2/4885KCNH2 563/4885CYP1A2 103/4885 |
| US-20170197942-A1 | SELECTIVE METHODS FOR THE SEPARATION OF ONDANSETRON AND RELATED IMPURITIES | HTR2C, HTR4, HTR2B | CYP3A4 23/4885KCNH2 478/4885CYP1A2 143/4885 |
| US-20080009635-A1 | One-Pot Process for the Preparation of Antiemetic Agent, 1,2,3,9-Tetrahydro-9-Methyl-3[(2-Methyl)-1H-Imidazole-1-Yl)Methyl]-4H-Carbazol-4-O | CRHR2, HCRTR2, HTR1D | CYP3A4 422/4885KCNH2 513/4885CYP1A2 219/4885 |
| US-10239866-B2 | Selective methods for the separation of ondansetron and related impurities | HTR2C, HTR4, HTR2B | CYP3A4 23/4885KCNH2 478/4885CYP1A2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.